While coping ahead is a helpful strategy for managing worry, dreading ahead causes a host of problems. Individuals can ...

Incannex Healthcare Inc. (Nasdaq: IXHL) , a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today reported that it holds approximately $75 ...

In early March 2026, Helus Pharma, a Cybin subsidiary, reported positive topline Phase 2 results for HLP004 as an adjunctive intramuscular treatment for adults with moderate-to-severe generalized ...

In this study, investigators aimed to explore outcomes following the development of mental health disorders after cancer diagnosis.

Medicinal cannabis might be increasingly available in many parts of the world, but a new review suggests it has no demonstrable benefit for depression or anxiety disorders. No proven benefit was ...

The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate(1) . The Drug ...

Asking caregivers if they are concerned about clutter or possible hoarding may help identify neurocognitive disorders, according to a study published in The Journal of Neuropsychiatry and Clinical ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced that it has regained compliance with ...

Older adults with prolonged grief disorder showed sustained symptom reduction following group or individual grief-focused cognitive behavioral therapy.

Behavioral and anxiety disorders were the most prevalent psychiatric diagnoses among US children during their first year of institutionalized care.

(Anastassiya Bezhekeneva/Getty Images) A large umbrella review has found no strong evidence to date that medicinal cannabis ...